# TBPH — Theravance Biopharma Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** TBPH  
**Sources:** 17  
**Published:** 2026-10-31  
**Canonical:** https://app.k3vl4r.com/research/deep-research-tbph-theravance-biopharma-inc-catalysts-narrative-risks-10408

---

As of October 31, 2026, **Theravance Biopharma Inc (TBPH)** is no longer a standalone publicly traded asset, as it has been acquired by **Zymeworks Inc (ZYME)** [[1]](https://markets.financialcontent.com/prnews/article/gnwcq-2026-9-28-zymeworks-announces-updated-2026-financial-guidance-and-final-transaction-details-following-theravance-biopharma-acquisition)[[3]](https://finance.yahoo.com/healthcare/articles/zymeworks-completes-acquisition-theravance-biopharma-103346331.html)[[16]](https://stockanalysis.com/stocks/tbph/forecast/).

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-tbph-theravance-biopharma-inc-catalysts-narrative-risks-10408 (free to sign up)._